Alkermes CEO Pops stays focused on 5461 filing plans; Shkreli gets booed at Harvard
• Alkermes $ALKS is moving ahead with plans to file a new depression drug, ALKS-5461, later in the year. “This is a fast-track designated medicine,” CEO Richard Pops told analysts in Wednesday’s quarterly call. “As we’ve done throughout the development process, earlier this week we met with FDA for a Type C scientific exchange to share with them the data from FORWARD-5. The meeting with FDA was productive, and we are on track with the plan submission of the NDA in the second half of the year.” And he is pushing ahead with a careful eye on ALKS-3831, “which is coming into focus as the pivotal program matures.”
• Martin Shkreli’s appearance at Harvard last night came with a string of heckling interruptions and protests from students. Price gouging on Daraprim? Oh, no, said the ex-Turing CEO. “It’s that everyone was getting a free ride before, not that this is price gouging,” Shkreli said, according to the Crimson. 1,400 people currently receive Daraprim for free, he claimed. “I wish no one got it for free, but the rules are they get it for free.”
• Pfizer has inked a broad ranging discovery pact with Washington University in St. Louis.